Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025477 | 0.98 | KDM4E (0.54) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL19908572 | 0.98 | KDM4E (0.54) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3741899 | 0.94 | KDM4E (0.57) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7535109 | 0.92 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3298738 | 0.88 | KDM4E (0.54) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7530909 | 0.86 | SMN1; SMN2 (0.56) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL18263421 | 0.84 | TP53 (0.58) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL23901544 | 0.82 | DRD2 (0.55) | KDM4ESMN1; SMN2KMT2AL3MBTL1POLB | |
| SCHEMBL7972561 | 0.82 | TP53 (0.61) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL7237460 | 0.82 | KDM4E (0.61) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| EP-2464353-B1 | TRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF MALARIA | CSIR (ZA) | 2017-03-29 | — | — | EP | disclosed |
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9249096-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249096-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140213588-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2013048982-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048982-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048930-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049096-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049096-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-2464353-A1 | TRIAZINE DERIVATES FOR USE IN THE TREATMENT OF MALARIA | CSIR (ZA) | 2012-06-20 | — | — | EP | disclosed |
| US-20120142920-A1 | TRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF MALARIA | CSIR (ZA) | 2012-06-07 | — | — | US | disclosed |
| WO-2011018742-A1 | TRIAZINE DERIVATES FOR USE IN THE TREATMENT OF MALARIA | CSIR (ZA) | 2011-02-17 | — | — | WO | disclosed |
| EP-1190710-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DIABETES | SHIONOGI & CO., LTD. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | KDM4E 4720/4885SMN1; SMN2 4637/4885ALDH1A1 1099/4885 |
| US-20120142920-A1 | TRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF MALARIA | CYP3A7, CCR7, CYP3A5 | KDM4E 2423/4885SMN1; SMN2 3258/4885ALDH1A1 2433/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | KDM4E 4720/4885SMN1; SMN2 4637/4885ALDH1A1 1099/4885 |
| US-20140213588-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, PNLIP, LPL | KDM4E 715/4885SMN1; SMN2 4684/4885ALDH1A1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.